Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Operating Leases (2020 - 2025)

Historic Operating Leases for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $53.1 million.

  • Lyell Immunopharma's Operating Leases fell 939.31% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.1 million, marking a year-over-year decrease of 939.31%. This contributed to the annual value of $51.0 million for FY2024, which is 1037.02% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Operating Leases is $53.1 million, which was down 939.31% from $55.1 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Operating Leases ranged from a high of $68.8 million in Q1 2022 and a low of $51.0 million during Q4 2024
  • In the last 5 years, Lyell Immunopharma's Operating Leases had a median value of $62.5 million in 2022 and averaged $61.8 million.
  • Per our database at Business Quant, Lyell Immunopharma's Operating Leases soared by 3079.66% in 2021 and then plummeted by 1037.02% in 2024.
  • Lyell Immunopharma's Operating Leases (Quarter) stood at $66.6 million in 2021, then dropped by 5.22% to $63.2 million in 2022, then decreased by 9.93% to $56.9 million in 2023, then dropped by 10.37% to $51.0 million in 2024, then rose by 4.08% to $53.1 million in 2025.
  • Its Operating Leases was $53.1 million in Q3 2025, compared to $55.1 million in Q2 2025 and $57.1 million in Q1 2025.